Inactive Instrument

News Kadimastem TEL AVIV STOCK EXCHANGE

Stocks

KDST

IL0011284614

Biotechnology & Medical Research

All News

09-28	Newcelx Ltd. Advances Ind-Enabling Activities for Ncel-101 Following Successful Fda Pre-Ind Meeting	CI
09-28	NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes	AQ
09-18	NewcelX Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-09	NewcelX Ltd. announced that it has received $1.399991 million in funding	CI
07-31	NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing	AQ
07-30	NewcelX Ltd. announced that it expects to receive $1.399991 million in funding	CI
07-15	NewcelX Obtains Patent in Brazil for Potential Type 1 Diabetes Treatment	MT
07-15	NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio	AQ
07-08	Newcelx Ltd. Announces Appointment of Camillo Ricordi to Scientific Advisory Board	CI
07-08	NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board	AQ
07-06	NewcelX Ltd. announced that it has received $2.940234 million in funding	CI
07-01	NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes	AQ
07-01	NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes	CI
06-15	NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology Platform	CI
05-27	Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes	RE
05-27	NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes	GL
05-27	NewcelX Submits Pre-IND Package To FDA For NCEL-101 For The Treatment Of Type 1 Diabetes	CI
04-30	NewcelX Ltd. announced that it has received $1.349994 million in funding	CI
04-29	NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-28	NewcelX Ltd. Auditor Raises 'Going Concern' Doubt	CI
04-20	Newcelx updates corporate presentation to highlight type 1 diabetes flagship program	RE
04-20	NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference	GL
04-01	NewcelX Ltd. announced that it expects to receive $1.349994 million in funding	CI
04-01	NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing	GL
03-09	NewcelX announces strategic collaboration with Eledon Pharmaceuticals to advance NCEL-101 program for type 1 diabetes	RE